Literature DB >> 3511935

Specificity of antibodies to the purified Con A acceptor glycoproteins of cultured tumour cells.

G L Koch, M J Smith.   

Abstract

Con A acceptor glycoproteins from the human Molt 4 (T cell leukaemia) and HeLa (endocervical adenocarcinoma) cell lines were purified by affinity chromatography and used for the preparation of rat antisera. Cross-absorption analysis showed that each antiserum contained antibodies which recognised cell surface antigens preferentially expressed by the donor cell line. Molt 4-associated antigens were fully expressed on T cell tumour lines and normal thymocytes, but not on non T cell tumour lines, peripheral blood lymphocytes or other blood cells. Immunofluorescence studies showed that the antigens were preferentially expressed on a sub-population of immature thymocytes. HeLa-associated antigens were only fully expressed on one other epithelial tumour cell in a panel of 17 cell lines. Immunofluorescence studies showed that the HeLa-associated antigens were expressed on normal endocervical adenoepithelium but not on ectocervical, endometrial or intestinal epithelia. Thus purified Con A acceptor glycoproteins of cultured tumour cell lines are potent immunogens for the generation of antibodies recognising lineage-associated differentiation antigens. These antigens should be useful in tumour classification and in the study of normal differentiation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511935      PMCID: PMC2001484          DOI: 10.1038/bjc.1986.3

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA.

Authors:  G E FOLEY; H LAZARUS; S FARBER; B G UZMAN; B A BOONE; R E MCCARTHY
Journal:  Cancer       Date:  1965-04       Impact factor: 6.860

2.  Transplantable human neoplasms maintained in cortisone-treated laboratory animals: H.S. No. 1; H.Ep. No. 1; H.Ep. No. 2; H.Ep. No. 3; and H.Emb.Rh. No. 1.

Authors:  H W TOOLAN
Journal:  Cancer Res       Date:  1954-10       Impact factor: 12.701

3.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Cellular and humoral immune responses to human urinary bladder carcinomas.

Authors:  J Bubeník; P Perlmann; K Helmstein; G Moberger
Journal:  Int J Cancer       Date:  1970-05-15       Impact factor: 7.396

Review 6.  Cross-contamination of cells in culture.

Authors:  W A Nelson-Rees; D W Daniels; R R Flandermeyer
Journal:  Science       Date:  1981-04-24       Impact factor: 47.728

7.  Marker profiles of human leukemia and lymphoma cell lines.

Authors:  J Minowada; H Koshiba; K Sagawa; I Kubonishi; M S Lok; E Tatsumi; T Han; B I Srivastava; T Ohnuma
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

Review 8.  Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia.

Authors:  M F Greaves
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

9.  Stability of the glycoproteins from a primary human pancreatic carcinoma during cell culture and in vivo passage in nude mice.

Authors:  G Koch; M J Smith; A G Grant; J Hermon-Taylor
Journal:  Br J Cancer       Date:  1983-04       Impact factor: 7.640

Review 10.  Phenotypic diversity in experimental hepatomas: the concept of partially blocked ontogeny. The 10th Walter Hubert Lecture.

Authors:  V R Potter
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

View more
  1 in total

1.  Antibodies specific for HeLa glycoprotein antigens are also specific for human endocervical epithelium.

Authors:  C Mujica van Herckenrode; D J Coleman; M Stanley; G L Koch
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.